Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra

Clin Lymphoma Myeloma Leuk. 2020 Sep;20(9):632-636.e1. doi: 10.1016/j.clml.2020.04.020. Epub 2020 May 11.

Affiliations

¹ Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY.
² Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
³ Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: Samir.Parekh@mssm.edu.

No abstract available

Keywords: Anakinra; CAR-T cell therapy; Cytokine release syndrome; Multiple myeloma; Tocilizumab.

Publication types

Case Reports
Research Support, N.I.H., Extramural

MeSH terms

Aged
Humans
Interleukin 1 Receptor Antagonist Protein / metabolism*
Male
Multiple Myeloma / genetics*
Multiple Myeloma / pathology
Receptors, Chimeric Antigen / genetics*

Substances

Interleukin 1 Receptor Antagonist Protein
Receptors, Chimeric Antigen

Grants and funding